Inotec AMD attains quality standard for medical product


20-10-2009

Inotec AMD Limited, developers of chronic wound treatments, has been found compliant with quality standard ISO13485:2003.

This award confirms that Inotec’s management and quality systems meet this critical medical device standard.

 

The company is expecting to complete two UK trials which are testing the functionality of the product on typical leg ulcers by March 2010.

 

Inotec AMD is a Cambridge Enterprise portfolio company. 

 

 

 

About Inotec AMD

www.inotecamd.com

 

Inotec AMD Limited was founded to commercialised two inventions that combine to make a novel, low-cost, compact wearable system for delivery of oxygen to the surface of wounds.  This is proven to promote the healing of hard-to-heal wounds, a $$-billion market, but prior to the work of Inotec was too expensive and inconvenient a treatment for significant use.  The Inotec system also has the added advantage of removing the infected exudate.  Inotec is now commencing trials of its system on real patients and is positioned to roll out its first product within a year.  Beyond this, the Inotec invention is a platform for other treatments and can be enhanced by telemedicine facilities.  The founding inventors have a record of success, having already collaborated to build a successful instrumentation company.

For further information please contact:

Inotec AMD Ltd
The Way, Fowlmere
Cambridge
SG8 7UJ

44 01763 207222
info@inotecamd.com

About Cambridge Enterprise Seed Funds

www.enterprise.cam.ac.uk    

 

Cambridge Enterprise Seed Funds is part of Cambridge Enterprise Limited and provides funding for early stage businesses that have been founded by members of the University of Cambridge. Cambridge Enterprise Seed Funds comprises the University Challenge Fund, the University Venture Fund and the University of Cambridge Discovery Fund.  The University Challenge Fund was established in 2000 as a result of a government initiative, with start up money from the University of Cambridge, the Wellcome Trust, the Gatsby Foundation and the Office of Science & Technology.  The University Venture Fund was set up in 1995 with Funds solely from the University of Cambridge.  The University of Cambridge Discovery Fund was launched in September 2008.  All three funds are evergreen and use equity realisations to continue funding new businesses.

 

Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge, responsible for the commercialisation of University intellectual property.  Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations.  Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring, specialist Surgeries and other related programmes. In 2007/08 income from licensing, consultancy and equity transactions exceeded £10 million, of which £8 million represents distributions to University departments and academics. For further information please contact: 

 

Shirley Jamieson

Head of Marketing

Cambridge Enterprise Limited 

Tel: 01223 760 339 email: shirley.jamieson@enterprise.cam.ac.uk

 

 

Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.

Cambridge Enterprise, University of Cambridge